Agreement between the IJC-IGTP-ICO: an essential step for research into leukaemia at the Can Ruti campus

The Institute for Health Science Research Germans Trias i Pujol (IGTP), the Catalan Institute for Oncology (ICO) and the Josep Carreras Leukaemia Research Institute (IJC) have signed a collaboration agreement to promote scientific research into leukaemia and other malignant blood diseases.


• The agreement creates a strategic alliance between the three institutions to promote joint scientific research in the field of leukaemia and other malignant blood diseases.

• The alliance will make it possible to bring together the large number of cases and samples that are necessary to produce relevant, high-quality studies. It also integrates the staff at the three institutions in order to carry out global and interdisciplinary research projects. In all, the agreement brings together more than a hundred staff members.

• The agreement establishes the conditions under which research programmes at the Can Ruti campus in Badalona will be carried out, it complements the agreement already signed with Hospital Clínic and the University of Barcelona, and will be followed by another agreement with Hospital de Sant Pau.

grup IJC dr. vives anemia

“Son minoritarias, graves y afectan a los niños, todo un reto para investigar”

• Con motivo del Día Mundial de las Enfermedades Raras (28 de febrero), el Instituto de Investigación contra la Leucemia Josep Carreras presenta una nueva línea de trabajo exclusivamente centrada en las anemias minoritarias.

• El 80% de las anemias minoritarias son diagnosticadas en los primeros años de vida lo que supone que apunten a enfermedades que afectan eminentemente a los niños. Son enfermedades graves y de muy difícil diagnóstico.

Cèl·lules mieloma múltiple

The Josep Carreras Leukaemia Research Institute participates in an important clinical study on multiple myeloma

• Dr. Albert Oriol, a hematologist at the Catalan Institute of Oncology/Germans Trias i Pujol Hospital, and researcher at the Josep Carreras Leukaemia Research Institute, takes part in an international study to assess a promising combination of drugs in the treatment of multiple myeloma.

• Multiple myeloma is still an incurable disease, but progress made over the last ten years has led to a very considerable improvement in the range of available treatments to combat it. One of these promising drugs is called daratumumab.

• In Spain there are 40 new cases of multiple myelomaper million inhabitants each year. 

Webpage updated 10/16/2019 13:23:15